Trials / Completed
CompletedNCT02729974
Use of ROTEM Intraoperatively in Women With Placenta Accreta
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- University of Utah · Academic / Other
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the use of rapid tests for hematocrit and clotting function in women undergoing surgery for placenta accreta. Half of participants will have these rapid tests performed during surgery to guide blood product transfusion and the other half will have standard lab tests performed to guide transfusion.
Detailed description
Placenta accreta has become an increasingly common pregnancy complication. Serious complications are common in patients with placenta accreta, including hemorrhage, transfusion of blood products, abdominal organ injury, bladder surgery, and ICU admission. Hemorrhage, or excessive blood loss, is the most common complication and often results in impaired ability for the body to form blood clots normally. The development of rapid testing of hematocrit and clotting function may allow for earlier identification of patients who have severe blood loss and development of clotting abnormalities. The investigators are testing whether use of this technology in patients undergoing surgery for placenta accreta, with earlier identification of patients with severe blood loss or clotting abnormality, will result in a lower need for transfusion and fewer complications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | ROTEM | rapid testing of blood clot formation |
| PROCEDURE | standard treatment | visual assessment of blood loss and clotting function every 30 minutes, combined with standard laboratory testing when indicated |
Timeline
- Start date
- 2016-05-08
- Primary completion
- 2024-12-01
- Completion
- 2025-12-01
- First posted
- 2016-04-06
- Last updated
- 2026-04-15
Source: ClinicalTrials.gov record NCT02729974. Inclusion in this directory is not an endorsement.